FDA Determines Regulatory Review Period for ROZLYTREK INJECTION Patent Extension

Summary

The US Food and Drug Administration has published a notice determining the regulatory review period for the patent extension of ROZLYTREK INJECTION, following a submission to the US Patent and Trademark Office.